ArticleEJNMMI research2015
The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.
Article in EJNMMI research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04934046 (Clinical Evaluation of a New Multipurpose Whole-body CZT Camera in DaTSCAN Brain Scintigraphy), which is not on this map. Cited by 72 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Evaluation of a New Multipurpose Whole-body CZT Camera in DaTSCAN Brain Scintigraphy: a Head-to-head Comparison With a Conventional System.
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Global Alterations of Whole Brain Structural Connectome in Parkinson's Disease: A Meta-analysis.Neuropsychology review · 2023Pooled it
- Hormonal contraceptives and the brain: A systematic review on 60 years of neuroimaging, EEG, and biochemical studies in humans and animals.Frontiers in neuroendocrinology · 2023Pooled it
- Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?Current opinion in psychiatry · 2021Pooled it
- Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.BMC neurology · 2021Trial
- Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD).Journal of Parkinson's disease · 2020Trial
- Equivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Up.Life (Basel, Switzerland) · 2026Review
- Editorial for "Mapping Neurodegenerative Changes in Clinically Uncertain Parkinsonian Syndrome Patients Using Fast MR Spin TomogrAphy in Time-Domain (MR-STAT) Relaxometry at 3 T".Journal of magnetic resonance imaging : JMRI · 2026Article
- Mapping Neurodegenerative Changes in Clinically Uncertain Parkinsonian Syndrome Patients Using Fast MR Spin TomogrAphy in Time-Domain (MR-STAT) Relaxometry at 3T.Journal of magnetic resonance imaging : JMRI · 2026Article
- Review
- Early Detection of Parkinson's Disease Using Automatic Classification of Single-photon Emission Computed Tomography Images.Healthcare informatics research · 2026Article
- Spectral presaturation with inversion recovery provides superior neuromelanin imaging for Parkinson's disease evaluation compared to magnetization transfer.Neuroradiology · 2026Article
- PREDICT-PD: A Two-Stage Approach to Early Identification of Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Let's celebrate 25 years of [European journal of nuclear medicine and molecular imaging · 2026Article
- Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database.Arquivos de neuro-psiquiatria · 2026Observational
- Towards a Biologically Defined Diagnosis: Incorporating Pathophysiological Measures Into Parkinson's Disease Clinical Criteria.Parkinson's disease · 2026Review
- Convolutional neural networks-based early Parkinson's disease classification using cycling data from a steerable indoor bicycle.Scientific reports · 2025Article
- Progress in Disease-Modifying Therapies for Parkinson's Disease.Aging and disease · 2025Review
- Trained dogs can detect the odor of Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Symptom improvement in a South Asian patient with Parkinson's disease treated with immediate- and extended-release carbidopa-levodopa: a case report.Journal of medical case reports · 2025Article
- Polygenic Risk Score Combined with Transcranial Sonography Refines Parkinson's Disease Risk Prediction.Movement disorders clinical practice · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In specialized movement disorder centers, Parkinson's disease (PD) is wrongly diagnosed in 6 to 25% of cases. To improve the accuracy of the clinical diagnosis, it is necessary to have a reliable and practical reference standard. Dopamine transporter single-photon emission computed tomography (DAT SPECT) imaging might have the potential (high diagnostic accuracy and practical to use) to act as reference standard in detecting nigrostriatal cell loss in patients with (early stage) parkinsonism. We performed a systematic review to evaluate if DAT SPECT imaging can be used as such. Relevant studies were searched in the MEDLINE and EMBASE databases. Studies were selected when they met the following criteria: (1) all patients were adults with a clinical diagnosis of PD or clinically uncertain parkinsonism and (2) the study reported original data. In addition, studies needed to fulfill one of the two following criteria: (1) patients underwent at least one DAT SPECT and had a neuropathological confirmed diagnosis and (2) patients underwent at least two DAT SPECT scans, performed at least 2 years apart. The search identified 1,649 articles. Eight studies fulfilled our selection criteria and were included in this review. There was only one study including patients with diagnostic uncertainty. Sensitivity and specificity of DAT SPECT imaging to detect nigrostriatal cell loss were 98%. The other studies included patients with a diagnosis of PD in whom there was no uncertainty. In these studies, sensitivity was 100%. Our systematic review indicates that DAT SPECT imaging seems to be accurate to detect nigrostriatal cell loss in patients with parkinsonism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.